✦ LIBER ✦

Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A

✍ Scribed by Claribel P. Taylor; Sanjeev Tummala; Deborah Molrine; Lisa Davidson; Richard J. Farrell; Anthony Lembo; Patricia L. Hibberd; Israel Lowy; Ciaran P. Kelly

Book ID: 116960554
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 202 KB
Volume: 26
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2008.04.042

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Two first-in-human, open-label, phase I

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers

✍ Barbara White; Francisco Leon; Wendy White; Gabriel Robbie 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Safety and pharmacokinetics of a human m

Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: A randomized, dose-escalation phase 1 study in adults

✍ Nithya Gogtay; Urmila Thatte; Nilima Kshirsagar; Brett Leav; Deborah Molrine; Pe 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 489 KB

An open-label, single-arm, phase I study

An open-label, single-arm, phase I study to evaluate the safety and immunogenicity of LBVH0101, a newHaemophilus influenzaetype b tetanus toxoid conjugate vaccine, in healthy adult volunteers

✍ Namhee Kim; Gyoungjin Choi; Chi-Yeon Lim; Jae-Won Lee; Kyung-Hyo Kim; Hoan Jong 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 367 KB

A randomized, open-label study to evalua

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

✍ Gary L. Davis; David R. Nelson; Norah Terrault; Timothy L. Pruett; Thomas D. Sch 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Collaborative Antiviral Study Group Chronic hepatitis C is the most common indication for liver transplantation, but viral recurrence is universal and progressive graft injury occurs in most recipients. Our aim was to assess the safety, pharmacokinetics (PK), and antiviral effects of high doses

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND,

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTS

✍ U. Lopatin; G. Wolfgang; R. Kimberlin; D. Turnas; M. Cornprost; G. Chittick; C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

162 A RANDOMIZED DOUBLE-BLIND, PLACEBO-C

162 A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF OCR-002 IN HEALTHY VOLUNTEERS

✍ P. Jochelson; J.L. van de Wetering; J. Bornstein; M. Resler; K. Anderson 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB